Skirmishing Disconcerting Covid-19 by Drug Reassigning

Author(s): Vikrant Nikam*, Shubham Mangulkar, Jyoti Khapare

Journal Name: Applied Drug Research, Clinical Trials and Regulatory Affairs
(Formerly Applied Clinical Research, Clinical Trials and Regulatory Affairs)

Volume 8 , Issue 1 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: COVID-19 is a most life threatening condition, therefore it is declared a pandemic by WHO as it has affected the whole world. Even though there are many advanced drug discoveries, viral afflictions are a broad area for researchers. Unfortunately, to date, no drug can treat this lethal infection. COVID -19 has raised the death rate crucially; therefore, it needs the reassigning of drugs for the control of affliction. In some cases, it shows that drug reassigning may cause adverse reactions. But in some countries, these drugs manifest fruitful effects for COVID patients. This article focuses on the effective drug moieties found in in-vitro studies. These drug moieties need further clinical testing based on their in-vitro clinical data. These moieties have shown hope as promising drugs for treating the deadly infection.

Objectives: The current manuscript is prepared with the main objectives of studying the various drugs and their benefits for the preparation of a vaccine for COVID-19 pandemics and studying the clinical trial status of drugs that are in the final stage of vaccine development.

Discussion and Conclusion: The vaccine development process is in progress, and has almost reached the final stage. There are drug reassignments for suppressing the COVID-19 by using various drugs such as Remdesivir, Sarilumab, Favipiravir, Tocilizumab, etc.; the whole world suffered a huge loss due to this pandemic, and the wait for the vaccine will be over shortly.

Keywords: COVID-19, coronavirus, clinical trials, vaccine, WHO, Remdesivir.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 20 December, 2020
Page: [63 - 69]
Pages: 7
DOI: 10.2174/2213476X07666201221110312
Price: $65

Article Metrics

PDF: 6